The FDA will revisit a device tomorrow that it cleared for U.S. sale three years ago — drug-eluting stents will be the ...
The American Heart Association has published a report demonstrating that adolescent boys have a significantly increased ...
The FDA was notified on Dec. 2 that Pfizer will suspend a large, Phase 3 trial evaluating the investigational ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
One of the major dilemmas faced by clinicians in the Intensive Care Unit (ICU) is the determination of volume status and ...
Toronto-based Cedara Software, a Merge Healthcare company and an independent developer of medical software technologies ...
Recent downplay of the media’s attention to DES-related thrombosis during both the TCT and AHA conferences this fall may ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
CV Therapeutics has announced it will file a new drug application to the FDA for its regadenoson agent in mid-2007 ...
Pulse oximetry, which directly monitors the patient's oxygenation, came into its own as standard medical practice 20 ...
The Society for Cardiac Angiography and Interventions (SCAI) has extended the abstract deadline for its 30th Annual ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Two novel polymer-free drug-eluting stent coating technologies tested in a comparative animal study has concluded with ...
Magnets may interfere with the operation of pacemakers and implantable cardioverter defibrillators (ICDs), according to a study published in the December 2006 edition of “Heart Rhythm.”
AngioDynamics, Inc. has announced FDA 510(k) clearance for Oncobionic, Inc. to market Irreversible Electroporation (IRE) ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Possis Medical, Inc. has received clearance from the FDA to market its AngioJet Xpeedior catheter to remove blood clots (thrombus) from upper- and lower-extremity peripheral veins. Used with the company’s AngioJet System, Xpeedior is the only device cleared for thrombectomy in peripheral veins.
An innovative lead insulation material for cardiac leads used with pacemakers and ICDs is now FDA approved and available ...
The Third International Conference on Cell Therapy for Cardiovascular Diseases will convene Jan 17 to 19, at The New York Academy of Medicine in New York, NY. The three-day program is dedicated to the evolving field of cell-based therapies for cardiac repair and regeneration.